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Abstract: PON1 has been demonstrated to be the serum enzyme responsible for detoxifying organophosphate chemical 
weapons and plays a protective role against atherosclerosis. In order to identify small molecules that modulate PON1 ac-
tivity in serum, we developed a high throughput kinetic absorbance assay using mouse serum and the organophosphate 
paraoxon. The IC50 value obtained for the known PON1 inhibitor, 2-hydroxyquinoline, matched the value reported for pu-
rified PON1. A compound library was screened resulting in no confirmed activators, but 12 confirmed inhibitors. Seven 
of these hits also inhibited purified human PON1. One compound was only two-fold less potent than 2-hydroxyquinoline 
in the serum assay, but 10-fold more potent against purified PON1. This compound (IC50 = 420 nM) may be useful to-
wards a chemical probe for PON1. Therefore, this assay has utility as a high throughput assay for discovery of small 
molecule modulators of PON1 activity that maintain activity in serum.  
INTRODUCTION  
  Atherosclerosis is the number one cause of mortality in 
Western societies [1]. Atherosclerosis is a disease affecting 
the arterial blood vessel where multiple plaques form on the 
arterial wall that grow in size to eventually reduce blood 
flow. When arteries that affect the heart are involved, the 
result is coronary heart disease (CHD). Epidemiological 
studies have identified multiple risk factors for CHD with 
one of the strongest being low levels of high-density lipopro-
tein (HDL) [2, 3]. HDL is a complex and heterogeneous par-
ticle with multiple proteins associated with it [4]. Apolipo-
protein A-I (apoA-I) is the major structural protein in HDL 
and it determines the structure and composition of the parti-
cle [5]. HDL appears to afford protection from atherosclero-
sis through at least two mechanisms, reverse cholesterol 
transport and inhibiting oxidation of low-density lipoprotein 
(LDL) [6]. The former property reduces the foam cell forma-
tion in plaques formed by cholesterol-loaded macrophages. 
Oxidized LDL has multiple proatherogenic properties, in-
cluding induction of cholesterol accumulation in macro-
phages, and potent pro-inflammatory, immunogenic, apop-
totic and cytotoxic activities.  
  Serum paraoxonase (PON1) is one of three members of 
the PON family of enzymes that includes PON2 and PON3 
[1]. PON1 and PON3 are secreted proteins found in the se-
rum, while PON2 is strictly an intracellular enzyme [1, 7-9]. 
PON1 and PON3 are expressed primarily in the liver, while 
PON2 is more widely expressed in a variety of tissues [7, 9]. 
The three human PON genes share approximately 65% ho-
mology at the amino acid level [10]. PON1 is a calcium-
dependent glycoprotein consisting of 354 amino acids with a 
molecular mass of approximately 43 kDa. The crystallization  
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of a variant of native PON1 revealed that PON1 has a six-
bladed  -propeller structure where each propeller contains 
four strands [11]. Two calcium ions are present in the pro-
tein, one is probably a structural calcium and the other is the 
catalytic calcium. PON1 was originally identified as the en-
zyme in serum capable of hydrolyzing the organophosphate 
paraoxon which is the toxic metabolite of the insecticide 
parathion [12-14]. In contrast to PON1, PON2 and PON3 
lack significant paraoxonase activity [15,16]. All three 
members of the PON family share the ability to hydrolyze 
aromatic and aliphatic lactones.  
  PON1 has been demonstrated to have three enzymatic 
activities – phosphotriesterase, arylesterase, and lactonase 
[16]. The most frequently used substrate for measuring 
PON1 phosphotriesterase activity is diethyl p-nitrophenol 
phosphate, known as paraoxon. This substrate is considered 
the most specific for measuring PON1 activity in serum 
since PON1 is the only serum enzyme that hydrolyzes par-
aoxon [17]. Phenyl acetate is the most frequently used sub-
strate to measure PON1 arylesterase activity because it is one 
of the best substrates for this enzyme [16]. More recent 
structure-reactivity studies with PON1 provide strong evi-
dence that its native activity is the lactonase activity [16]. 
However, the physiological substrates for PON1 are still 
unknown.  
  There is a growing body of evidence that implicates a 
role for PON1 in protection from atherosclerosis. Serum 
PON1 is almost exclusively found associated with HDL par-
ticles and preferentially associates with apoA-I containing 
HDL particles in vivo and in vitro [1,18]. PON1 has sub-
nanomolar affinity (Kd <10
-9 M) for apoA-I HDL, a signifi-
cantly higher affinity than for other lipoproteins [18]. In ad-
dition, apoA-I HDL stimulates PON1 catalytic activity. 
ApoA-I HDL stimulated PON1 paraoxonase and arylesterase 
activity (using phenyl acetate) by approximately 2-fold and 
5-fold, respectively, while the lactonase activity of PON1 
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data provides evidence that apoA-1 activates the catalytic 
activity of PON1. PON1 knockout mice (C57BL/6J strain) 
showed enhanced susceptibility to organophosphate toxicity 
and atherosclerosis induced by a high fat, high cholesterol 
diet [17]. HDLs from PON1-deficent mice were unable to 
prevent LDL oxidation by cells in vitro and HDLs and LDLs 
from these mice were more susceptible to oxidation than the 
lipoproteins from wild-type mice. Many other in vitro stud-
ies have shown that PON1 inhibits oxidation of lipid in LDL 
and HDL [9,19]. In addition, transgenic mice over-
expressing PON1 show a dose dependent decrease in athero-
sclerotic lesions with increasing expression of PON1 [20]. 
PON1 has also been shown to inhibit macrophage choles-
terol accumulation by several mechanisms, including at-
tenuation of cellular uptake of oxidized LDL by the scaven-
ger receptor CD36, inhibition of macrophage cholesterol 
biosynthesis, and stimulation of macrophage cholesterol ef-
flux [21-23]. The His115-His134 catalytic dyad of PON1 is 
essential for PON1-mediated inhibition of LDL oxidation 
and stimulation of macrophage cholesterol efflux, indicating 
that PON1 enzymatic activity is required for at least these 
two in vitro anti-atherogenic functions [24]. PON1 has been 
shown to induce lysophosphatydalcholine (LPC) in macro-
phages and that LPC generation in macrophages by PON1 is 
dependent on the His catalytic dyad [24]. LPC was shown to 
directly stimulate rHDL mediated cholesterol efflux from 
macrophages. Taken together, these data suggested a model 
wherein PON1 lactonase activity is responsible for lactoniz-
ing oxidized lipids in LDL or cells and then hydrolyzing the 
resultant lactones to free the carboxylic acid and LPC.  
  In humans, PON1 activity is inversely related to the risk 
of cardiovascular diseases [25]. A recent study of the distri-
bution and activity of PON1 in diabetes patients found an 
abnormal serum PON1 distribution [26]. In a prospective 
study using men in South Wales, PON1 paraoxonase activity 
was demonstrated to be a predictive risk factor for CAD in-
dependent of other established risk factors [27]. The PON1 
activity in individuals varies by 10- to 40-fold [25]. Smok-
ing, degraded cooking oil, and trans fats have all been re-
ported to lower PON1 activity [28-30]. In contrast, polyphe-
nols, moderate alcohol consumption and the cholesterol low-
ering drug simvastatin have all been reported to increase 
PON1 activity [31-33]. Therefore, one of the antiatherogenic 
effects of statins may be through indirect transcriptional 
upregulation of PON1 gene expression. A recent in vitro 
study demonstrated that aspirin dramatically up-regulated the 
transcription of PON1 in HepG2 cells and normal rat hepa-
tocytes [34]. Taken together, research on PON1 has led to 
the hypothesis that therapeutic agents that increase serum 
PON1 activity may have antiatherogenic activity in humans. 
In addition, therapies that cause a rapid short term enhance-
ment of PON1 catalytic activity may be advantageous in 
protection pre- or post-exposure to some organophosphate 
nerve agents. Thus, a small molecule drug that is able to 
immediately increase the catalytic activity of PON1 already 
in the blood may have therapeutic advantages in protection 
from chemical warfare agents. 
  Herein we describe the development and proof-of-
principle testing of a high throughput assay for discovery of 
small molecule activators and inhibitors of PON1 activity. 
Serum was used as the source of PON1 where it is closest to 
its native environment. In addition, any resulting hits will 
have at least some activity at high serum concentrations. 
Small molecule activators of PON1 may have use as re-
search tools and/or lead to therapeutic agents, while potent 
and selective inhibitors of PON1 could be useful as research 
tools in exploring the biological function of PON1.  
MATERIALS AND METHODOLOGY  
Reagents  
  All common reagents such as Tris-HCl, CaCl2, and di-
methyl sulfoxide (DMSO) were reagent-grade quality ob-
tained from Thermo Fisher Scientific (Waltham, MA) or 
Sigma-Aldrich (St. Louis, MO). 2-hydroxyquinoline (2HQ), 
paraoxon and phenyl acetate were also obtained from Sigma-
Aldrich. Raw untreated mouse serum was purchased from 
Biomeda Corporation (Foster City, CA) and Genetex, Inc 
(San Antonio, TX). Purified human PON1 (catalog # 
0801384) was obtained from ZeptoMetrix Corporation (Buf-
falo, NY). The 384-well plates (catalog #3702) for the serum 
assay were from Corning Incorporated (Corning, NY) and 
for the purified PON1 assay, UV transparent plates (catalog 
# 781801) from Greiner Bio-One (Monroe, NC) were used. 
The compounds for screening and IC50 determinations were 
obtained from the Asinex Corporation (Moscow, Russia).  
Serum Paraoxonase Assay 
  The assay was developed with a final volume of 50 l 
and in 384-well plate format to match the intended screening 
format. The serum paraoxonase assay was performed by the 
addition of compound to the well of a 384-well plate fol-
lowed by the addition of diluted serum and then the reaction 
was initiated by addition of the paraoxon. Compounds, se-
rum, and paraoxon were diluted with assay buffer consisting 
of 50 mM Tris pH 8.0 and 1 mM CaCl2. In assay develop-
ment experiments done by hand, typically the volumes for 
compound (or DMSO), serum and paraoxon were 10, 20, 
and 20 l, respectively, giving a final volume of 50 l. The 
automated assay used different volumes as described below, 
but with the same final reagent concentrations. The paraoxon 
was used at the final concentration of 1 mM which is close 
to its reported Km value [16] and the commonly used con-
centration for measuring PON1 activity. Immediately after 
initiation of the reaction with paraoxon, the plate was read in 
kinetic mode in a SpectraMax384 (Molecular Devices, 
Sunnyvale, CA) at a wavelength of 410 nm. After a 5 second 
plate shake by the instrument, a total of 4 reads for every 
well were taken with one read performed every 33 seconds. 
The velocity of the reaction in milli-absorbance units per 
minute (mU/min) was calculated by linear regression by the 
instrument software. Assay development experimental data 
points were performed in at least triplicate determination. 
Error bars for data points represent standard deviations. Z’-
factor values were derived by the published formula with Z’-
factors of 0.5 – 1.0 indicating that an assay is robust for 
screening [35].  
High Throughput Screen 
  For the high throughput screening of the Asinex chemical 
library, 0.5 μl of 1 mM compound in 100% DMSO was 
added to dry 384-well plates using a Biomek NX (Beckman 
Coulter, Inc., Fullerton, CA), resulting in a final compound 
concentration of 10 μM for the primary screen. This dry 
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routine HTS method of conserving compound stock solu-
tions. This spotting method has been validated for transfer of 
0.5 μl DMSO with a CV of 6.3% and relative inaccuracy of -
2.0%. The Biomek NX automated liquid dispenser was also 
used to deliver all assay reagents to the wells. To the plates 
containing compound, 40 μl of mouse serum diluted in assay 
buffer was added to give a final concentration of 15% serum. 
Subsequently, 10 μl of paraoxon diluted in assay buffer was 
added with the BioMek NX, followed immediately by a ki-
netic read of the plate in the plate reader. Final assay concen-
trations were 15% serum, 1 mM paraoxon, 10 M com-
pound, 1% DMSO (from compound), 0.5% methanol (from 
paraoxon stock solution) and 1x assay buffer. Maximum 
(max) signal positive control wells contained only DMSO 
(no compound), while the minimum (min) signal control 
wells were obtained by using EDTA. The definition of a hit 
was a compound that displayed 50% inhibition in the pri-
mary screen or 75% activation. IC50 value was defined as the 
concentration of inhibitor calculated to inhibit 50% of the 
assay signal based on a serial dilution of compound. Values 
were calculated using either a four or three-parameter dose 
response (variable slope) equation in Graphpad Prism or 
ActivityBase (IDBS, Alameda, CA). For the IC50 determina-
tions, serial dilutions of compounds were performed in 100% 
DMSO with a two-fold or three-fold dilution scheme result-
ing in 8-10 concentrations of compound starting at a high 
concentration of 10-80 μM compound in the final assay. For 
the HTS assay, these compound dilutions were spotted onto 
plates and the assay performed at 1% DMSO final concen-
tration as described for the primary screen.  
Purified PON1 Assay 
  The assay using purified PON1 was similar in format to 
the serum paraxonase assay except for the following 
changes. PON1 (type AA) purified from human serum was 
purchased from ZeptoMetrix and used in the assay instead of 
serum. Phenyl acetate was used at 1 mM and the phenol 
product detected by absorbance measured at 270 nm in UV 
transparent 384-well plates. Since these assays were per-
formed by hand instead of by automation, the assay volumes 
were changed. All reagent dilutions were done using assay 
buffer. To the bottom of the well, 10 l of compound dilu-
tion was added followed by 20 l of PON1 enzyme diluted 
in assay buffer. The final concentration of enzyme was 15 
ng/well or 7 nM. After addition of enzyme, 20 l of phenyl 
acetate diluted in assay buffer was added to start the reaction 
giving a final volume of 50 l. The plate was then immedi-
ately read in the plate reader (without plate shaking) to gen-
erate initial velocity values. Final DMSO concentrations 
were kept at 0.25 to 0.5% DMSO.  
RESULTS 
Assay Optimization 
  The optimal concentration of serum to use in the serum 
PON1 assay was determined by varying the percentage of 
serum in the final reaction (Fig. 1). The rate of the reaction 
increased in a linear fashion up to 15% serum, after which it 
became non-linear. The reason for the loss in linearity, i.e. 
lower than expected velocities at >15% serum concentra-
tions, appears to be due to the high absorbance of the serum; 
studies in which the reactions were stopped and diluted 
show a linear increase in product up to the highest concentra-
tion of serum tested (60%) (data not shown). The serum 
concentration that was chosen was 15% and this concentra-
tion was used in all subsequent experiments. The linearity of 
the reaction was determined over extended times to provide 
information on how quickly the reaction needed to be read in 
the plate reader after initiation of the reaction with substrate 
(Fig. 2). The reaction rate was linear for at least 20 minutes 
indicating that there is ample time to read the plate after ad-
dition of paraoxon.  
 
 
 
 
 
 
 
 
 
 
Fig. (1). Reaction velocities at different serum concentrations. 
Reaction velocities in milli-absorbance units per minute 
(mU/min) were obtained for the indicated serum concentrations 
measured as percentage of the final reaction. Data points were 
performed in triplicate determination and error bars represent 
standard deviations. Data are representative of two independent 
experiments. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Reaction time course. Absorbance (optical density) was 
recorded over time for six replicate reactions initiated at time 0. 
Serum concentration was 15%. Error bars represent standard 
deviations. Data are representative of two independent experi-
ments.  
 
  Since the compounds to be screened were dissolved in 
DMSO, the tolerance of the assay for DMSO was deter-
mined (Fig. 3). The assay was very sensitive to DMSO with 
some inhibition observed at 0.5 and 1% DMSO. These re-
sults are consistent with a report that various organic sol-
vents inhibit recombinant purified PON1 enzymatic activity 
[16]. We chose to use 1% DMSO in the testing of com-
pounds. The stability of the diluted serum at 23°C (room 
temperature) was determined over time and the activity in 54    Current Chemical Genomics, 2008, Volume 2  Graves and Scott 
the serum was stable for at least 60 minutes (data not 
shown).  
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). DMSO Tolerance. Reaction velocities were determined 
at the indicated concentrations of DMSO, in percentage of the 
final reaction. Data points were performed in triplicate determi-
nation and error bars represent standard deviations. 
 
  To validate that the observed catalytic activity was de-
rived from PON1 in the serum, the assay was used to deter-
mine the IC50 for the known PON1 inhibitor, 2-
hydroxyquinoline (2HQ) (Fig. 4).  
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). IC50 value determination for 2HQ using serum par-
aoxonase assay. Reaction velocities were measured at the indicated 
2HQ concentrations. Final DMSO concentration all 2HQ concen-
trations was 1%. Data points were performed in triplicate determi-
nations and error bars represent standard deviations. Data are repre-
sentative of three independent experiments. The average IC50 value 
of all experiments was 7.9 M.  
 
  The assay was performed at a constant 1% DMSO at all 
concentrations. The average IC50 value obtained was 7.9 μM 
for 2HQ. This IC50 value is in good agreement with the pub-
lished Ki value of 3 M for recombinant variant of PON1 
[15]. The Cheng-Prusoff equation that relates IC50 to Ki sug-
gests the expected IC50 value to be twice the Ki value when 
using a substrate at its Km value. This is close to what was 
observed using this assay where the substrate was used at a 
concentration that closely matched the reported Km value. In 
addition, the average absolute Hill slope of the IC50 curves 
was 1.0 which is in agreement with the ideal value of 1.0 
expected when measuring inhibition of a single enzyme. 
Taken together, this data suggests that our PON1 assay is 
measuring PON1 and only PON1 enzymatic activity. 
Assay Variability  
  The variability of the assay described above was charac-
terized in a 384-well plate format (Fig. 5). The HTS version 
of the serum PON1 assay employed work station level 
automated liquid handling system using the Biomek NX for 
delivery of compound or DMSO (0.5 l), diluted serum (40 
l), and paraoxon (10 l), in that order. The use of the 
Multidrop (Thermo Fisher) liquid handling instrument was 
tested for delivery of serum to the plate but automation pat-
tern artifacts were observed possibly due to the viscous na-
ture of the diluted serum. To assess variability of the assay 
with full automation, all wells of a 384-well plate, except for 
two columns used as controls, were pre-spotted with 0.5 μl 
of DMSO.  
 
 
 
 
 
 
 
 
 
 
Fig. (5). Serum paraoxonase assay variability assessment. All 
wells of a 384-well plate, except for two columns used as con-
trols, were pre-spotted with 0.5 l of DMSO. The pre-spotted 
DMSO plates simulated compound plates to be screened. One 
plate each was used to determine the maximum signal (), mini-
mum signal using EDTA (), and a 2x serum concentration () 
to mimic 2x activation of enzymatic activity. The variability for 
inhibition was determined using the max and min plates while 
the activation window was determined based on the max and 2x 
plates. The Z’-factors for the inhibition assay window and the 
activation assay window are provided. Data are representative 
of two independent experiments.  
 
  The pre-spotted DMSO plates simulated compound 
plates that were to be screened. The desired screen was one 
that could detect both activators and inhibitors of PON1 that 
could function in serum. Therefore, one plate each was used 
to determine the maximum (max) signal, minimum (min) 
signal using EDTA to inactivate PON1, and a 2x serum 
concentration to mimic 2x activation of enzymatic activity. 
This analysis of variability was done twice. The variability 
for inhibition was determined using the max and min plates 
while the activation window was determined based on the 
max and 2x plates. The % CV of the max and 2x plates were 
all between 6 and 8%, while the %CV relative to the assay 
window for the min plates was 0.8 and 1.4 %. The Z’-
factors for the inhibition assay window were 0.72 for both 
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0.76 and 0.79. Thus, the assay was highly robust with good 
variability amenable for high throughput screening for both 
activators and inhibitors of serum paraoxonase activity.  
HTS Results 
  A diverse collection of 28,400 small organic molecules 
purchased from Asinex Corporation were screened for PON1 
activation or inhibition (Fig. 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). High throughput screening of a chemical library. The 
single point screening data is shown in a scattergram showing 
percent inhibition for each compound tested. The cut-off for in-
hibition (upper line) and activation (lower line) are shown with 
dotted lines. Activation values result in negative percent inhi-
bition values. The average Z’-factor using the plate controls was 
0.73. 
 
  Each plate had max controls with just DMSO spotted in 
the wells and min controls where a solution of 
EDTA/DMSO was used. At the time this assay began 
screening compounds, software limitations prevented calcu-
lations of both inhibition and activation and therefore 2x 
activation controls were not performed for the screen. Com-
pound plates were pre-spotted with 0.5 l of 1 mM com-
pound in 100% DMSO. To these compound plates, 40 l of 
diluted serum was added followed by 10 l of paraoxon such 
that the final concentration of compound was 10 M and 1% 
DMSO, serum was 15%, and 1 mM paraoxon. Using the 
plate controls, the calculated average Z’-factor for the whole 
screen was 0.73 and a day-to-day range of 0.69 to 0.77. The 
screen resulted in 36 actives displaying 50% inhibition and 
123 actives with 75% increased activity (calculates as -75% 
in inhibition formula). Thus, the active rates were 0.13% and 
0.43% for inhibition and activation, respectively. The use of 
75% activation was chosen to avoid too many compounds 
for follow-up. The activator actives were triaged by manual 
inspection of the time course data to reduce false positives 
due to aberrant points or plotting by the instrument software. 
After this manual inspection, 51 activator actives (0.18%) 
were re-tested in IC50 format where none of them confirmed 
activity. 
Inhibitors Identified 
  In contrast to the activator hits, 12 of the 36 inhibitor hits 
confirmed activity in IC50 determinations, ranging from 8.5 
to 26.6 M (Table 1). The structures of these inhibitors are 
quite diverse but had some similar scaffold motifs within the 
group of hits. The most potent one, compound 1, with an 
IC50 value of 8.5 M, was similar in potency to 2HQ, but 
very different in structure, having a 1,3,4 thiadiazole scaf-
fold. Compounds 1 and 2 share this scaffold and compound 
3 could be considered a related compound with similar “R-
groups”, but a isoxazole core instead of the thiadiazole core. 
There were three hits with an identical 1,4 dihydro-
pyrano[2,3-c] pyrazole core scaffold (compounds 4 - 6) and 
two hits had a pyrimidine core scaffold (compounds 9 and 
10). Four hits were “singlets” without similar scaffolds 
within the hit series (compounds 7, 8, 11, 12). These com-
pounds had core scaffolds that included a benzo-quinazo-
linone (compound 7), a quinolinone (compound 8), a thi-
azepinone (compound 11) and a aza-bicyclo-octane-2-4-
dione (compound 12). Thus, this serum PON1 assay was 
successful in finding inhibitors that functioned in the pres-
ence of a high concentration of serum.  
  Potential inhibitors of paraoxonase activity could have 
multiple potential targets due to the complexity of serum. To 
test whether these compounds directly inhibited PON1, these 
hits were tested for inhibitory activity using purified human 
PON1, instead of serum, in a similar format assay except 
phenyl acetate was used as the substrate. Phenyl acetate was 
used instead of paraoxon since phenyl acetate is a better sub-
strate that allowed less enzyme to be used in the reaction, 
thus conserving PON1 enzyme. The standard inhibitor 2HQ 
inhibits this purified enzyme assay with an IC50 of 4.4 M, 
similar to the IC50 generated using the serum-based assay 
(Table 1) and the reported Ki value of 3 M [15]. The twelve 
hits from the screen were initially screened at a single com-
pound concentration of 20 M in triplicate to determine 
which ones inhibit purified human PON1 arylesterase activ-
ity (Table 1). Seven of the compounds displayed >50% inhi-
bition at 20 M concentration. Thus, 58% of the screen hits 
using mouse serum also inhibited purified human PON1. Six 
of these gave average percent inhibition values similar to or 
higher than 2HQ. Subsequently, the IC50 values were deter-
mined for these six hits using purified PON1 (Table 1). 
Compounds 4 and 11 gave average IC50 values of 5.3 and 4.8 
M, respectively, which is nearly identical to the potency 
obtained for 2HQ in the same assay which was 4.4 M. Two 
compounds, compounds 3 and 7, were significantly more 
potent than 2HQ. Compound 3, with an isooxazole core 
structure, produced an IC50 of 0.76 M which is 5-fold more 
potent than 2HQ in the purified PON1 assay. Compound 7, 
with a benzo-quinazolinone core structure, yielded an IC50 of 
420 nM. Thus, compound 7 was only two-fold less potent 
than 2HQ in the serum assay, but 10-fold more potent than 
2HQ in the purified PON1 assay. In addition, the average 
Hill slope value determined from the IC50 determinations 
was 0.96, which is very close to the ideal Hill slope value of 
1.0. This suggested that the mechanism of inhibition for 
compound 7 is likely to be via single site binding and not 
through compound aggregation or non-specific chemical 
modification of the enzyme. The latter mechanisms usually 
significantly shift the Hill slope value of IC50 curves [36]. 
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Table 1.  Activities of Confirmed Inhibitors from Chemical Library Using Serum-Based and Purified PON1 Assays 
Purified PON1  
Compound Asinex  Identifier 
a  Structure 
Serum PON1  
IC50 (M) 
b  % Inhibition 
c IC50 (M) 
d 
2HQ N/A 
N O H
 
7.9 84  4.4 
1 ASN  08910296 
N S
N
O
N
 
8.5 90  10.6 
2 ASN  08912428 
N S
N
O
N
N
 
18.6 13  n.d.
 e 
3 BAS  09529674  N
O
N O  
15.3 103  0.76 
4 BAS  01369653 
O N
H
N
H2N
N
 
10.3 90  5.3 
5 BAS  09683917 
O N
H
N
H2N
N
O
HN O
O
 
21.8 -2  n.d. 
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(Table 1). Contd….. 
Purified PON1 
Compound Asinex  Identifier 
a  Structure 
Serum PON1 
IC50 (M) 
b  % Inhibition 
c IC50 (M) 
d 
6 BAS  09683916 
O N
H
N
H2N
N
O
HN O
O
 
26.6 6  n.d. 
7 BAS  03551158 
N
NH
O
HN
OH  
12.5 103  0.42 
8 ASN  05298740 
H
N
O
O O
N
N N
NN
 
13.2 12  n.d. 
9 BAS  05307909 
HN
O
S
H
N
N
O  
14.9 70  n.d. 
10 BAS  02915353  N
N
S H2N
HN
O
O
O
 
18.4 19  n.d. 
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(Table 1). Contd….. 
Purified PON1  
Compound Asinex  Identifier 
a  Structure 
Serum PON1  
IC50 (M) 
b  % Inhibition 
c IC50 (M) 
d 
11 BAS  09588626 
S
O
O
H
N
O
O
 
20.6 92  4.8 
12 BAS  01814176  N
O
O
OH
O
 
21.1 18  n.d. 
aChemical identifier number provided by Asinex Corporation. 
bIC50 value determined by the serum paraoxonase assay. 
cCompounds were tested at 20 M in triplicate determinations for each compound. Data are average % inhibition values from two experiments. 
dData are average IC50 values determined from two independent experiments, except for compounds 1 and 6. 
eNot determined. 
DISCUSSION 
  Unlike many serum enzymes, PON1 is anchored in lipo-
protein particles - specifically HDL particles. This localiza-
tion appears to be important for PON1's role in preventing 
oxidation of HDL and LDL. It has been postulated that 
PON1 removes oxidized lipid molecules and hence the im-
portance of it residing at the surface of the lipid - its sub-
strates. Thus, PON1 resides in a somewhat unique environ-
ment shared by few other serum enzymes. In addition to its 
atheroprotective role, PON1 also detoxifies some organo-
phosphate toxins. Thus, small molecules that enhance 
PON1's activity could have potential therapeutic value in 
slowing atherosclerosis and/or in protection from certain 
organophosphate-class chemical weapons. In addition, po-
tent inhibitors that have activity in serum could be useful 
research tools for in vivo and in vitro experiments.  
  Lipids, interacting proteins and other factors may modify 
PON1 activity. Examples of this have been reported, includ-
ing lipids that enhance PON1 activity [37] and phosphate 
binding protein which appears to stabilize PON1 structure 
[38]. Therefore, it is conceivable that small molecules activa-
tors of PON1 may be discovered that either bind to PON1 
directly and activate its activity or modify protein-protein 
interactions through binding to PON1-associated proteins. In 
order to potentially discover either type of activator, it was 
the goal of this work to develop a high throughput assay that 
could detect activators, as well as inhibitors, of PON1 activ-
ity. It was also desirable to maintain PON1 in its native envi-
ronment and conformation associated with the lipid surface 
of HDL particles. Therefore, mouse serum was chosen as a 
source of native PON1. The use of paraoxon as the substrate 
for PON1 allowed the specific detection of PON1 activity 
even in the presence of many serum enzymes.  
  An assay was developed to screen chemical libraries for 
small molecule activators and inhibitors of paraoxonase ac-
tivity in serum. PON1 has been shown to be the only enzyme 
in mouse serum that can hydrolyze paraoxon. Therefore, the 
source of PON1 used for this PON1 assay was pooled un-
treated mouse serum and the substrate was paraoxon. Pheno-
typic cell-based screens are used for screening and character-
izing the biological activity of compounds. In analogy to 
these cell based assays, we have developed a serum-based, 
rather than cell-based, enzyme assay. Use of serum instead 
of purified PON1 for a screen has several potential advan-
tages. First, PON1 is closer to its native environment, and 
potentially its structural conformation, in serum relative to 
purified enzyme. Native PON1 in serum is bound to the lipid 
of HDL particles in close proximity with other proteins such 
as apoA-I and phosphate binding protein which has been 
shown to associate with PON1 and stabilize it [38, 39]. Sec-
ondly, with the use of whole serum there is the chance of 
discovering compounds that modify protein-protein interac-
tions that directly or indirectly affect PON1 activity or stabil-
ity. Thirdly, hits obtained from such a screen will be more 
likely to function in the high protein environment of serum. 
Lastly, the high protein content in the assay would be ex-
pected to make the assay highly resistant to ‘nuisance’ hit 
compounds that inhibit purified enzyme assays through ag-
gregation or covalent modification of the enzyme.  
  In this report, a kinetic absorbance assay was developed 
to measure PON1 activity. This is an assay that has tradi-
tionally been used to measure PON1 activity, but a high 
throughput version of the assay using serum as source of 
enzyme has not been reported previously. The kinetic nature 
of this assay, as opposed to end point assays, has several 
advantages. The primary advantage is that colored or other-
wise interfering compounds should not be detected as false 
positives since the assay measures the rate of increase in 
optical density so colored compounds that absorb will start 
out at a higher optical density, but have an unchanged rate of 
increase if they are inactive. However, theoretically there is 
potential to measure the dissolution of absorbing compounds 
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falsely appear to increase the reaction rate. Additionally, the 
linear progress of the reaction can always be verified by ex-
amining the raw data which provides assurance of measuring 
initial rates even if the assay protocol is changed. Hits can be 
triaged by examination of the linear progression of the reac-
tion to see the quality of the fit, i.e. R
2 of the linear fit done 
by the instrument software. Non-linear progressions were 
suspect.  
  The choice of 15% serum concentration was based on the 
serum concentration that generated a robust reaction rate 
(slope) while avoiding turbid higher concentrations that may 
have interfered with the assay. In time course experiments, 
this assay remained linear with time for at least 10 minutes 
which allowed plenty of time between the start of the assay 
and reading the plate. The DMSO tolerance data indicated 
the activity is very sensitive to DMSO, with even 0.5 and 1% 
DMSO inhibiting PON1 activity. This is consistent with the 
reported sensitivity of PON1 to organic solvents [16]. To 
verify activity was from PON1 in the serum, the IC50 value 
was determined with the assay using 2HQ and the values 
obtained matched the reported Ki. In addition, the Hill slope 
of the 2HQ IC50 data indicated the inhibition of a single en-
zyme.  
  Whole 384-well plate variability studies using pre-
spotted DMSO plates and automation were done to assess 
the variability in detection of both inhibitors and activators. 
The results generated Z’-factors of >0.7 for both activators 
and inhibitors, indicating a robust assay for detection of both 
types of hits.  
  Screening of the commercially supplied compound set 
resulted in 123 activators initially identified in the single 
point screen. A significant number of these (59%) were eas-
ily eliminated by examination of the raw data which showed 
abnormal reaction progressions (curving of the reaction pro-
gression or an abnormal point that resulted in inaccurate lin-
ear regression). This type of false positive may result from 
the measurement of light absorbing compounds dissolving 
into solution from its original 100% DMSO solvent. The 
remaining activator actives, represented 0.18% of the total 
compounds screened, did not repeat activity in IC50 assays. 
Subsequent to the completion of the screen, it was discov-
ered that changing a couple of procedures could potentially 
decrease the false positive rate for activators. Typically, 
when the plate was put into the plate reader for kinetic reads, 
the program was set up to shake the plate for 5 seconds prior 
to taking the first data point. It was discovered that not shak-
ing the plate before the reads began actually decreased vari-
ability. Furthermore, better data was obtained by waiting a 
approximately 2-3 minutes to read the plate after the initia-
tion of the reaction. This time lag may allow the reaction 
components (compound, serum and paraoxon) to mix thor-
oughly and reach a steady reaction rate and allow time for 
dissolution of light absorbing compounds.  
  One possible reason that none of the 51 activators could 
be confirmed may be that these actives were poorly soluble 
light absorbing compounds and the apparent increase in ve-
locity was actually a result of the compounds slowly dissolv-
ing into solution. The lack of repeatable “activity” in IC50 
assays may have been due to a somewhat longer time lag 
between the start of the reaction and plate reading. This 
longer time lag may have allowed the compounds to become 
fully dissolved in solution, i.e. reach equilibrium, before the 
first read time and hence not contribute to the increase in 
absorbance with time. Another possible explanation for the 
lack of confirmation of activators may simply be due to vari-
ability in the activation aspect of the assay, leading to false 
positives. Since 2x activation controls could not be per-
formed at the time of screening due to software limitations, 
the activation variability could not be assessed for the screen. 
However, the assay development data using 2x the concen-
tration of serum in variability studies suggested that the as-
say had reasonable variability in detecting activators.  
  Seven of the 12 inhibitors (58%) had some activity 
against human purified PON1. All three of the most potent 
inhibitors discovered in the screen also inhibited purified 
PON1. This data further validated that the screening assay 
was measuring PON1 activity in the serum. The discovery of 
inhibitors to purified PON1 demonstrated the utility of the 
assay to discover inhibitors of PON1 that would maintain at 
least some inhibitory activity in the presence of serum. There 
are several possible reasons for the lack of activity against 
purified PON1 for some of the hits. One possibility is that 
the purified PON1 is of human origin unlike the mouse 
PON1 in the serum screen. Though the two species have 
high homology (85%), they are not identical and compound 
binding sites may have variation. To fully characterize the 
species specificity and activity of the hits, they should be 
tested for activity in assays using purified mouse PON1 and 
human serum. One other possibility is that some compounds 
may lack aqueous solubility in the absence of facilitating 
serum protein. In fact, precipitating material in compound 
dilutions were observed in experiments with compounds 5 
and 6, which could explain their lack of activity in the puri-
fied PON1 assay. Another possibility for variation in results 
between the two PON1 assays is that different substrates 
were used and different residues are required for catalysis of 
these substrates. However, splitting inhibition of these activi-
ties by a small molecule seems unlikely since only one active 
site has been identified for PON1 and 2HQ inhibits both ac-
tivities approximately equally (see Table 1). A final possibil-
ity is that the inhibitor acts on a PON1 associated molecule 
that is present in serum and influential to PON1 activity, yet 
absent in the purified version of PON1. 
  Interestingly, many new scaffolds unrelated or only dis-
tantly related to 2HQ were discovered to inhibit PON1. It 
should be noted that several of the structures contain lactam 
motifs (compounds 7, 8, 9, 11, 12) and simple lactams have 
been reported to weakly inhibit PON1 [40]. The difference in 
the activity observed in the serum assay and the purified 
PON1 assay for active compounds varied from nearly the 
same (compound 1) to a 30-fold shift (compound 7). This is 
most likely due to compound binding to serum protein and 
thus shifting the IC50 in the presence of serum. Compound 7 
had IC50 values in the serum assay and the purified PON1 
assay of 12.5 and 0.42 M, respectively. This 10-fold in-
crease in potency over 2HQ is noteworthy and suggests that 
this compound may be a useful research tool. Compounds 1 
and 4 are attractive inhibitors because they show less than a 
two-fold shift in potency in the presence of serum and could 
be starting points for the discovery of more potent inhibitors 
of PON1 for research use. An advantage to the compounds 
described in this report is that they are all commercially 
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CONCLUSIONS  
  We have developed a high throughput kinetic absorbance 
assay for discovery of small molecule modulators of PON1 
activity. The use of mouse serum as the source of PON1 
helped ensure that hits in this assay maintain activity in the 
presence of serum and allowed PON1 to be screened closer 
to its native environment. The enzyme specificity of this 
assay was confirmed with the known PON1 inhibitor 2HQ. 
Variability studies confirmed the robustness of this assay for 
high throughput screening. A chemical library was screened 
resulting in no confirmed activators, but 12 confirmed in-
hibitors. The most potent inhibitors had potencies within 
two-fold of 2HQ, but were structurally unrelated. These in-
hibitors were tested to determine if they could inhibit the 
activity of purified human PON1. Seven of the twelve hits 
from the screen inhibited purified human PON1. One com-
pound was only two-fold less potent than 2HQ in the serum 
assay, but 10-fold more potent than 2HQ using purified 
PON1. With an IC50 of 420 nM, this compound may be use-
ful in the development of a chemical probe for PON1.  
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